Home > Rheumatology > ACR 2022 > ACR 2022 Congress Round-Up > No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies

No increased cancer risk in patients with rheumatic diseases and prior malignancy treated with novel therapies

Presented By
Dr Juan Molina Collada , Gregorio Marañón General University Hospital, Spain
Conference
ACR 2022
Trial
BIOBADASER
Doi
https://doi.org/10.55788/c3dd6474
A cohort study revealed that cancer risk in patients with rheumatic diseases and a history of previous malignancy did not differ significantly based on the type of biological disease-modifying antirheumatic drugs (DMARDs) and targeted synthetic DMARDs exposure. Besides, there was no difference between those under anti-TNF therapy versus other DMARDs.    More and more patients with rheumatic diseases are treated with novel therapies, including biological and targeted synthetic DMARDs. Though these patients generally have a higher prevalence of comorbidities, including cancer, available robust data on the malignancy risk is limited. A cohort study including 352 patients investigated the occurrence and relative risk of incident cancer in those with rheumatic diseases and prior malignancy treated with DMARDs [1]. The study selected patients from the multicentre, prospective Spanish BIOBADASER registry (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on